Table 2.
Median Overall Survival Times (Months) by Subgroup
| Median OS (95 % CI) | Log-rank p-value | |
|---|---|---|
| Total | 8.91 (6.05-13.55) | |
| Treatment | ||
| DCT | 8.60 (5.36-16.1) | |
| AXL | 8.91 (5.46-16.5) | 0.66 |
| Age | ||
| <65 years | 8.91 (5.36-14.5) | |
| ≥65 years | 7.14 (6.05-NA) | 0.4 |
| Sex | ||
| Female | 13.6 (7.53-22.4) | |
| Male | 7.00 (5.36-12.6) | 0.16 |
| Subtype | ||
| Adenocarcinoma | 12.6 (4.87-18.3) | |
| Squamous cell carcinoma | 8.09 (6.55-13.32) | 0.12 |
| WHO performance status | ||
| 0 | 16.5 (5.36-NA) | |
| 1 | 7.14 (5.46-13.3) | |
| 2 | 10.1 (1.32-NA) | 0.13 |
| Hgb | ||
| <110 g/L | 6.05 (3.45-NA) | |
| ≥110 g/L | 9.41 (6.48-15.0) | 0.097 |
| WBC | ||
| ≤9 x 109/L | 12.3 (7.53-17.1) | |
| >9 x 109/L | 4.24 (3.22-11.3) | 0.002 |
| Plt | ||
| ≤350 x 109/L | 12.6 (6.55-16.1) | |
| >350 x 109/L | 4.24 (3.45-23.6) | 0.094 |
DCT, Docetaxel; AXL, AXL1717; Hgb, Hemoglobin; WBC, White blood cells; Plt, Platelets; SD, Standard deviation; OS, Overall survival